The next project meeting will be organized on 14 December 2021 as a virtual meeting.
EURAMET website of the Project is here.
About this project
Primary standards and traceable measurement methods for X-ray emitting electronic brachytherapy devices (PRISM-eBT) is a joint research project within the European Metrology Programme for Innovation and Research (EMPIR). The project began on 1 July 2019 and will run for three years, finishing on 30 June 2022. The overall goal of this project is to carry out pre-normative research on electronic brachytherapy (eBT) to simplify and harmonise eBT dosimetric procedures and provide metrological input to standardisation bodies. The Chief stakeholder of the project is the International Atomic Energy Agency.
Download Publishable Summary of the project.
The specific objectives are:
- To establish primary standards for the absorbed dose rate to water for eBT devices at 1 cm depth of water for internal radiotherapy. To evaluate currently used transfer instruments and corresponding measurement procedures and to establish simple and robust tools for dissemination of the absorbed dose rate to water to clinical practice.
- To establish a dosimetric methodology for superficial eBT aligned with or similar to the recommendations for superficial (skin) external radiotherapy given in International Atomic Energy Agency – Technical Reports Series (IAEA-TRS) 398, Deutsches Institut für Normung (DIN) 6809-4, Nederlandse Commissie voor Stralingsdosimetrie (NCS)-10 and Institute of Physics and Engineering in Medicine (IPEM). The target uncertainty for the conversion of dose at the surface (i.e. 70 μm) to dose at 1 cm depth is 5 %.
- To characterise detectors and measurement instruments suitable for the determination of 3D dose distributions in water by eBT devices. To develop a standardised traceable calibration process for these detectors, allowing a reduction in the uncertainties in dose, dose distribution and dose-effectrelation to a level recommended in IAEA Human Health Report No 31. The aim is to achieve uncertainties (k = 1) for the calibration coefficients of not more than: 1 % – 2 % (NMIs) and 2 % – 3 % (clinic) for the scintillation detectors and for the small volume ionisation chambers, 3.5 % for the gel dosimeter and 2.5 % for the alanine pellets.
- To provide traceable dosimetry for 3D dose distribution measurements for at least three eBT commercial systems for which no dosimetry system currently exists and to make them available for the end user community.
- To contribute to the development of technical work of IAEA and others where appropriate to ensure that the outputs of the project are aligned with their needs, communicated quickly to those developing the standards and to those who will use them, and in a form that can be incorporated into the standards at the earliest opportunity.
More detailed results from reports internal to the project may be made available to individual enquirers.